Spots Global Cancer Trial Database for p16
Every month we try and update this database with for p16 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older | NCT02328313 | Breast Cancer Aging Physical Activi... | Walk with Ease ... | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | NCT01530997 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin Limited surgica... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer | NCT01688323 | Head and Neck C... | Collect Blood a... | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer | NCT02167932 | Breast Cancer Aging | Walk With Ease | 21 Years - 59 Years | UNC Lineberger Comprehensive Cancer Center | |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | NCT05419089 | HPV-positive Or... | Robotic surgery | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | NCT06332092 | Head and Neck S... | FID007 | 18 Years - | Fulgent Pharma LLC. | |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | NCT05419089 | HPV-positive Or... | Robotic surgery | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older | NCT02328313 | Breast Cancer Aging Physical Activi... | Walk with Ease ... | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | NCT01530997 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin Limited surgica... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | NCT06332092 | Head and Neck S... | FID007 | 18 Years - | Fulgent Pharma LLC. | |
| p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management | NCT02522585 | Cervical Cancer | Conservative ma... | 18 Years - | Parc de Salut Mar | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer | NCT01267357 | Serous Papillar... | no intervention | 18 Years - | Rambam Health Care Campus | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
